HYDERABAD
– Sai Life Sciences Restricted (BSE: 544306 I NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a devoted Peptide Analysis Middle at its built-in R&D Campus in Hyderabad, India.
Asserting the launch, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, mentioned: “Because the pharmaceutical trade evolves from small molecules to rising modalities like peptides, we’re increasing our capabilities to remain forward. Our new Peptide Analysis Middle displays this dedication—designed to satisfy the rising demand for complicated peptide synthesis and conjugation. With this funding, we reinforce our position as a trusted accomplice in advancing next-generation therapeutics.”
The Peptide Analysis Middle is designed to help innovator pharma and biotech corporations with specialised companies throughout peptide synthesis, discovery, and superior modalities, together with complicated conjugates. The power integrates automation, superior liquid dealing with, robotics, and high-throughput programs, enhancing precision, scalability, and effectivity within the growth of novel peptide-based therapeutics.
Maneesh Pingle, Head of Discovery Providers, mentioned: “The demand for peptide-based therapeutics is rising quickly, pushed by their excessive specificity, biocompatibility, and decrease threat of off-target results. At Sai Life Sciences, now we have a seasoned crew of scientists with years of expertise efficiently delivering peptide discovery and growth initiatives. Mixed with our increasing capabilities, this experience positions us strongly to help our shoppers’ evolving wants as they advance peptide therapies throughout numerous therapeutic areas.”
The brand new Peptide Analysis Middle shall be built-in with Sai Life Sciences’ end-to-end discovery companies, spanning artificial and medicinal chemistry, biology, DMPK, and toxicology. This holistic method ensures seamless transitions throughout completely different phases of drug discovery, accelerating timelines and enhancing success charges for peptide-based drug growth.
By combining deep experience, cutting-edge know-how, and an built-in method, Sai Life Sciences strengthens its dedication to supporting international shoppers in advancing progressive peptide therapeutics.
About Sai Life Sciences:
Sai Life Sciences is an innovator-focused Contract Analysis, Improvement, and Manufacturing Group (CRDMO) that works with over 300 international innovator pharma and biotech corporations to speed up the invention, growth, and commercialisation of their NCE small molecule programmes. Over the previous 25 years, Sai Life Sciences has served a various set of programmes, persistently delivering worth primarily based on its high quality and responsiveness. The corporate has over 3,000 staff throughout its amenities in India, UK, USA and Japan. https://www.sailife.com/
